{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-271112","form_type":"8-K","ticker":"ALXO","cik":"0001810182","company_name":"ALX ONCOLOGY HOLDINGS INC","filed_at":"2025-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.541741+00:00","generated_at":"2026-05-16T23:06:54.492937+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ALX Oncology Q3 net loss improves to $0.41/share; highlights evorpacept benefit in CD47-high gastric cancer","bullets":["GAAP net loss for Q3 2025 was $22.1M ($0.41/share), improved from $30.7M ($0.58/share) in Q3 2024.","Cash, cash equivalents and investments at Sept 30, 2025: $66.5M; runway into Q1 2027.","ASPEN-06 exploratory analysis: In CD47-high retained HER2+ gastric cancer, evorpacept combo achieved 65.0% ORR vs 26.1% for control; median DOR 25.5 vs 8.4 months.","Phase 1 ALX2004 (EGFR-targeted ADC) cleared first dose cohort; currently enrolling 2 mg/kg dose; initial safety data expected 1H 2026.","Barbara Klencke, M.D., appointed interim Chief Medical Officer; brings 30+ years oncology drug development experience."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-271112","json":"https://secwatch.observer/filing/0001193125-25-271112.json","markdown":"https://secwatch.observer/filing/0001193125-25-271112.md","text":"https://secwatch.observer/filing/0001193125-25-271112.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810182/000119312525271112/0001193125-25-271112-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810182/000119312525271112/alxo-20251107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:06:54.492937+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}